Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2015 | Novel HDAC6 inhibitor, ricolinostat, for the treatment of multiple myeloma

At the Myeloma 2015 meeting, Dr Noopur Raje (Massachusetts General Hospital, Boston, MA) discusses the clinical development of the selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat, for the treatment of multiple myeloma. Clinical results to date suggest that ricolinostat is likely to operate synergistically with other agents.